Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 12/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.34 |
| ▸ | GRK2 | P25098 | 2/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.32 |
| ▸ | PRKACA | P17612 | 1/20 | 0.32 |
| ▸ | PRKACG | P22612 | 1/20 | 0.32 |
| ▸ | PRKACB | P22694 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL699831 | 0.86 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL694742 | 0.84 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL694926 | 0.84 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL693668 | 0.82 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL695613 | 0.82 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL695328 | 0.82 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL694992 | 0.81 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL695587 | 0.81 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL2680185 | 0.80 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL706446 | 0.73 | DGAT1 (0.42) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421864-B1 | 1-PYRAZOLO[4,3-C]ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-08-06 | — | — | EP | disclosed |
| US-8461175-B2 | 1-pyrazolo[4,3-c]isoquinoline derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2013-06-11 | — | — | US | disclosed |
| US-20120115898-A1 | 1-PYRAZOLO[4,3-C]ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-05-10 | — | — | US | disclosed |
| EP-2421864-A1 | 1-PYRAZOLO[4,3-C]ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010122272-A1 | 1-PYRAZOLO[4,3-C]ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115898-A1 | 1-PYRAZOLO[4,3-C]ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CBR3, CYP4F3, HCCS | ROCK2 1357/4885ROCK1 989/4885DGAT1 3755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.